Tottenham agree new long-term deals with midfield duo Nabil Bentaleb and Harry Winks

Tottenham have agreed new long-term deals with midfield duo Nabil Bentaleb and Harry Winks. The former is an established first-team star after coming through the academy, while the latter has had an impressive season for the youth team earning him a three-year extension.

"The Club is delighted to announce that Nabil Bentaleb has signed a new five-year contract, which runs until 2020," a statement on Spurs' official site reads.

The Algerian midfielder, who rose through the ranks at the club, has become an integral part of the first-team at White Hart Lane and formed a solid midfield partnership with fellow academy graduate Ryan Mason.

Bentaleb joined the north London club as a trialist in September 2011, before signing academy forms in January the following year. He made his Spurs debut against Southampton in December 2013, and went on to make a further 19 appearances that season.

The 20-year-old midfielder played a key role in helping his Algerian national team reach the knockout stages of the 2014 World Cup in Brazil, after which he was also part of his country's Africa Cup of Nations squad earlier this year.

A London Evening Standard report earlier in the year suggested that the midfielder was not happy with the deal initially offered, as he wanted his wages to be on par with colleagues Harry Kane and Christian Eriksen, who are reportedly on the £40,000-a-week package, while the Algerian international was being offered £25,000-a-week.

Winks, on the other hand, is just making his way into the first-team with his debut coming at the end of last year in a Europa League game against Partizan Belgrade. He was a key player for the Spurs' U21 team and will be keen on making it to the first-team squad and emulate the likes of Kane and Mason, who stepped up last summer.

"Young midfielder Harry Winks has signed a new contract with the Club until 2018, with the option of an additional further year," Tottenham's official site confirmed.